PurGenesis Technologies, Inc.
🇨🇦Canada
Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis
Phase 2
Completed
- Conditions
- Atopic Dermatitis Eczema
- Interventions
- Drug: Administration of PlaceboDrug: Administration of PUR0110 (Thykamine) 0.05%Drug: Administration of PUR0110 (Thykamine) 0.1%Drug: Administration of PUR0110 (Thykamine) 0.25%
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- PurGenesis Technologies Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT03540043
- Locations
- 🇨🇦
SimcoDerm Medical and Surgical Dermatology Center, Barrie, Ontario, Canada
🇨🇦Manna Research Inc. (Burlington North), Burlington, Ontario, Canada
🇨🇦DermEffects, London, Ontario, Canada
Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis
Phase 2
Completed
- Conditions
- ProctosigmoiditisLeft-Sided Ulcerative Colitis
- Interventions
- Drug: PUR 0110 Rectal Enema 250 mgDrug: PUR 0110 Rectal Enema 500 mgDrug: Placebo EnemaDrug: PUR 0110 Rectal Enema 1000 mg
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- PurGenesis Technologies Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT01149707
- Locations
- 🇩🇪
PurGenesis Investigational Site, Werden, Germany
A Study to Assess the Safety and Tolerability of PUR 0110 Rectal Enema in Normal Healthy Volunteers
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: PUR 0110 Rectal Enema or Placebo Enema
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2010-06-24
- Lead Sponsor
- PurGenesis Technologies Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01149694
- Locations
- 🇩🇪
FOCUS Clinical Drug Development GmbH Phase 1 Clinic, Neuss, Germany
News
No news found